Wang Jing, Ju Bomiao, Zhu Li, Li Hanchao, Luo Jing, Zhang Jing, Hu Nan, Mo Lingfei, Wang Yanhua, Pan Ying, Huang Jing, Lv Xiaohong, Pu Dan, Hao Zhiming, He Lan, Li Yuanyuan
Department of Rheumatology and Immunology, First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi, China.
Front Pharmacol. 2023 Feb 16;14:1080730. doi: 10.3389/fphar.2023.1080730. eCollection 2023.
To examine the kinetics of B cell subsets and activation markers in the early stage of belimumab treatment and their correction with treatment response. We enrolled 27 systemic lupus erythematosus (SLE) patients receiving 6 months belimumab treatment. Flow cytometry was used to test their B cell subsets and activation markers (including CD40, CD80, CD95, CD21, CD22, p-SYK and p-AKT). During belimumab treatment, SLEDAI-2K declined, the proportions of CD19 B cells and naïve B cells decreased, whereas the switched memory B cells and non-switched B cells increased. The larger variations of the B cell subsets and the activation markers were in the first 1 month than the other later time frames. The ratio of p-SYK/p-AKT on non-switched B cell at 1 month was associated with the SLEDAI-2K decline rate in the 6 months of belimumab treatment. B cell hyperactivity was rapidly inhibited in the early stage of belimumab treatment, and the ratio of p-SYK/p-AKT may predict SLEDAI-2K decline. https://www.clinicaltrials.gov/ct2/show/NCT04893161?term=NCT04893161&draw=2&rank=1; identifier: NCT04893161.
为研究贝利尤单抗治疗早期B细胞亚群和激活标志物的动力学变化及其与治疗反应的相关性。我们纳入了27例接受6个月贝利尤单抗治疗的系统性红斑狼疮（SLE）患者。采用流式细胞术检测其B细胞亚群和激活标志物（包括CD40、CD80、CD95、CD21、CD22、p-SYK和p-AKT）。在贝利尤单抗治疗期间，SLEDAI-2K评分下降，CD19+B细胞和幼稚B细胞比例降低，而转换记忆B细胞和未转换B细胞增加。B细胞亚群和激活标志物在前1个月的变化比其他后续时间段更大。治疗1个月时未转换B细胞上p-SYK/p-AKT的比值与贝利尤单抗治疗6个月时SLEDAI-2K的下降率相关。贝利尤单抗治疗早期B细胞的高活性被迅速抑制，p-SYK/p-AKT比值可能预测SLEDAI-2K的下降。https://www.clinicaltrials.gov/ct2/show/NCT04893161?term=NCT04893161&draw=2&rank=1；标识符：NCT04893161 。
